Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2 S1 mRNA vaccine
- Development stage
- Preclinical
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A **SARS-CoV-2 S1 mRNA vaccine** is an mRNA-based prophylactic vaccine construct designed to deliver messenger RNA encoding the **S1 subunit of the SARS-CoV-2 spike glycoprotein**, with the goal of inducing host-cell expression of the viral antigen and generating neutralizing antibody and T-cell responses against COVID-19. Mechanistically, the administered mRNA is translated in host cells, the encoded S1 antigen is presented to the immune system, and vaccination is intended to elicit adaptive immunity directed primarily against the spike S1 region, including receptor-binding epitopes involved in viral attachment to **angiotensin-converting enzyme 2**. The term as given does not identify a single unique commercial or clinical-stage product, developer, manufacturer, formulation, or exact construct, and is therefore best treated as a **non-specific descriptor of an mRNA vaccine concept** rather than a uniquely identifiable drug entity.
- Other names
- SARS-CoV-2 S1 mRNA vaccineSARS-CoV2 S1 mRNA vaccineSARS-CoV 2 S1 mRNA vaccine
02
Targets
S1 (SARS-CoV-2 spike S1 subunit)
Beyond the preview
Go deeper on SARS-CoV-2 S1 mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 S1 mRNA vaccine.